213 related articles for article (PubMed ID: 25354654)
1. Risk factors for fracture among current, persistent users of bisphosphonates.
LeBlanc ES; Rosales AG; Balasubramanian A; O'Malley CD; Egbuna O; Friess D; Perrin NA
Osteoporos Int; 2015 Feb; 26(2):713-25. PubMed ID: 25354654
[TBL] [Abstract][Full Text] [Related]
2. Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries.
Wang Z; Ward MM; Chan L; Bhattacharyya T
Osteoporos Int; 2014 Aug; 25(8):2109-16. PubMed ID: 24846316
[TBL] [Abstract][Full Text] [Related]
3. The Association Between Long-Term Bisphosphonate Use and the Risk of Fracture Among Women Aged 50 or Older with Osteoporosis.
Wang CC; Lu HT; Dusetzina SB; Wu CH
J Womens Health (Larchmt); 2016 Jul; 25(7):738-46. PubMed ID: 27096405
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonate use and subsequent hip fracture in South Korea.
Lee YK; Ha YC; Choi HJ; Jang S; Park C; Lim YT; Shin CS
Osteoporos Int; 2013 Nov; 24(11):2887-92. PubMed ID: 23681088
[TBL] [Abstract][Full Text] [Related]
5. Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan.
Soong YK; Tsai KS; Huang HY; Yang RS; Chen JF; Wu PC; Huang KE
Osteoporos Int; 2013 Feb; 24(2):511-21. PubMed ID: 22588182
[TBL] [Abstract][Full Text] [Related]
6. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates.
Hadji P; Claus V; Ziller V; Intorcia M; Kostev K; Steinle T
Osteoporos Int; 2012 Jan; 23(1):223-31. PubMed ID: 21308365
[TBL] [Abstract][Full Text] [Related]
7. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis.
Imaz I; Zegarra P; González-Enríquez J; Rubio B; Alcazar R; Amate JM
Osteoporos Int; 2010 Nov; 21(11):1943-51. PubMed ID: 19967338
[TBL] [Abstract][Full Text] [Related]
8. Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases.
Olsen KR; Hansen C; Abrahamsen B
Osteoporos Int; 2013 Oct; 24(10):2639-47. PubMed ID: 23604250
[TBL] [Abstract][Full Text] [Related]
9. Adherence to osteoporosis medications amongst Singaporean patients.
Cheen MH; Kong MC; Zhang RF; Tee FM; Chandran M
Osteoporos Int; 2012 Mar; 23(3):1053-60. PubMed ID: 21503813
[TBL] [Abstract][Full Text] [Related]
10. Osteoporotic fracture rate among women with at least 1 year of adherence to osteoporosis treatment.
Modi A; Tang J; Sen S; Díez-Pérez A
Curr Med Res Opin; 2015 Apr; 31(4):767-77. PubMed ID: 25708648
[TBL] [Abstract][Full Text] [Related]
11. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonate use after clinical fracture and risk of new fracture.
Bergman J; Nordström A; Nordström P
Osteoporos Int; 2018 Apr; 29(4):937-945. PubMed ID: 29397408
[TBL] [Abstract][Full Text] [Related]
13. Subjects with osteoporosis to remain at high risk for fracture despite benefit of prior bisphosphonate treatment-a Danish case-control study.
Hansen L; Petersen KD; Eriksen SA; Gerstoft F; Vestergaard P
Osteoporos Int; 2017 Jan; 28(1):321-328. PubMed ID: 27475930
[TBL] [Abstract][Full Text] [Related]
14. A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System.
Devine J; Trice S; Finney Z; Yarger S; Nwokeji E; Linton A; Davies W
Osteoporos Int; 2012 Apr; 23(4):1415-24. PubMed ID: 21786005
[TBL] [Abstract][Full Text] [Related]
15. Increased fracture risk after discontinuation of anti-osteoporosis medications among hip fracture patients: A population-based cohort study.
Fu SH; Wang CY; Hung CC; Lee CC; Yang RS; Huang CC; Farn CJ; Lin WH; Chen HM; Hsiao FY; Lin JW; Li CY
J Intern Med; 2021 Dec; 290(6):1194-1205. PubMed ID: 34237171
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonates and mortality: confounding in observational studies?
Bergman J; Nordström A; Hommel A; Kivipelto M; Nordström P
Osteoporos Int; 2019 Oct; 30(10):1973-1982. PubMed ID: 31367949
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk.
Mignot MA; Taisne N; Legroux I; Cortet B; Paccou J
Osteoporos Int; 2017 Dec; 28(12):3431-3438. PubMed ID: 28875236
[TBL] [Abstract][Full Text] [Related]
18. Incidence of second hip fracture and compliant use of bisphosphonate.
Lee YK; Ha YC; Yoon BH; Koo KH
Osteoporos Int; 2013 Jul; 24(7):2099-104. PubMed ID: 23247329
[TBL] [Abstract][Full Text] [Related]
19. Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis.
Liu J; Guo H; Rai P; Pinto L; Barron R
Osteoporos Int; 2018 Nov; 29(11):2409-2417. PubMed ID: 30022254
[TBL] [Abstract][Full Text] [Related]
20. Examining the Effect of Medication Adherence on Risk of Subsequent Fracture Among Women with a Fragility Fracture in the U.S. Medicare Population.
Keshishian A; Boytsov N; Burge R; Krohn K; Lombard L; Zhang X; Xie L; Baser O
J Manag Care Spec Pharm; 2017 Nov; 23(11):1178-1190. PubMed ID: 29083977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
